53084-60-9

Basic information

• Product Name: Cyclohexanecarboxylic acid, 3-amino-, ethyl ester
• CAS NO: 53084-60-9
• Molecular Formula: C9H17NO2
• Molecular Weight: 171.239
• Mol File: 53084-60-9.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Cyclohexanecarboxylic acid, 3-amino-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxylic acid, 3-amino-, ethyl ester(53084-60-9)
• EPA Substance Registry System: Cyclohexanecarboxylic acid, 3-amino-, ethyl ester(53084-60-9)

Safety Data

• Hazardous Substances Data: 53084-60-9(Hazardous Substances Data)

Upstream product

• 582-33-2 3-aminobenzoic acid ethyl ester 
• 1259278-09-5 ethyl (1R,3S)-3-benzyloxycarbonylaminocyclohexane-1-carboxylate 
• 2927-71-1 2,4-dichloro-5-fluoropyrimidine 
• 227783-08-6 (1S,3R)-3-ethoxycarbonylcyclohexane-1-carboxylic acid 
• 16636-51-4 3-aminocyclohexanecarboxylic acid 
• 99-05-8 meta-aminobenzoic acid 
• 64-17-5 ethanol 

Downstream Products

• 1259366-99-8 ethyl (1R,3S)-3-((2-chloro-5-fluoropyrimidin-4-yl)amino)cyclohexane-1-carboxylate 
• 1259367-00-4 (1R,3S)-3-((2-chloro-5-fluoropyrimidin-4-yl)amino)cyclohexane-1-carboxylic acid 
• 1259367-01-5 N-((1R,3S)-3-((2-chloro-5-fluoropyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 
• 1383446-18-1 N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 
• 1383446-73-8 N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 
• 925921-14-8 3-hydroxymethyl-1-cyclohexylamine 
• 1259367-02-6 N-((1R,3S)-3-(5-fluoro-2-(5-fluoro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)cyclohexyl)pyrrolidine-1-carboxamide 
• 1383485-54-8 (1R,3S)-ethyl 3-(6-bromo-3,5-difluoropyridin-2-ylamino)cyclohexanecarboxylate 
• 1383485-77-5 (1R,3S)-3-(3,5-difluoro-6-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexanecarboxylic acid 
• 1383485-56-0 (1R,3S)-3-(3,5-difluoro-6-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexanecarboxylic acid 
• 1383485-55-9 (1R,3S)-ethyl 3-(3,5-difluoro-6-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexanecarboxylate 
• 1383375-93-6 (1R,3S)-3-((5-cyano-4-(5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)cyclohexanecarboxylic acid 
• 1259278-12-0 benzyl N-[(1S,3R)-3-aminocyclohexyl]carbamate 
• 1261225-49-3 [3-(1R,3S)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester 

Relevant articles and documents

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

PROBLEM TO BE SOLVED: To provide inhibitors of influenza virus replication. SOLUTION: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient comprise administering to the biological sample or patient an effective amount of a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A compound is represented by structural formula (IA) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. COPYRIGHT: (C)2015,JPO&INPIT

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.